お知らせ • Dec 10
Veradigm Inc. Announces CEO Changes
On December 8, 2023, Veradigm Inc. (the “Company”) announced that the Board of Directors of the Company (the “Board”) appointed current Chairman of the Board, P. Gregory Garrison, as Executive Chairman of the Board, and appointed current director, Dr. Shih-YinHo, as Interim Chief Executive Officer of the Company, each effective December 7, 2023. Mr. Garrison and Dr. Ho will both remain on the Board, and Dr. Ho will serve the Company as principal executive officer. In addition, the Company announced that Leland Westerfield will serve the Company as Interim Chief Financial Officer and will serve as the Company’s principal financial officer and principal accounting officer, effective December 7, 2023. Following Mr. Garrison’s appointment as Executive Chairman, Carol J. Zierhoffer was appointed as Lead Independent Director. As a result of the previously disclosed, ongoing independent investigation by the Audit Committee of the Board that relates to the Company’s financial reporting, internal controls over financial reporting and disclosure controls, on December 6, 2023, Richard J. Poulton and Leah S. Jones each resigned at the request of the Board from their positions as Chief Executive Officer and Chief Financial Officer, respectively, effective immediately. Mr. Poulton also stepped down from the Board, effective December 6, 2023. Ms. Jones will continue serving the Company as a consultant for an initial period of six months. Dr. Ho, age 53, is a seasoned digital health, software, and pharmaceutical services entrepreneur, executive, and advisor, having spent over 20 years developing products and companies in health information infrastructure, data analytics, and decision support for life sciences. Dr. Ho has served as President of Glimpse LLC (“Glimpse”), an independent software and strategy consulting firm for pharmaceutical services companies, since October 2018. During her time at Glimpse, she also served as the Chief Strategy Officer and Chief Product Officer of Aetion Inc. (“Aetion”), a client of Glimpse and provider of real-world evidence software solutions for life science companies and payers, from March 2019 through March 2020. Dr. Ho also served as the Chief Executive Officer and Co-Founder of Last Mile Research, an organization she co-founded in July 2021 focused on changing and optimizing the way life sciences companies source talent for clinical trials, until November 2023. In addition, prior to Glimpse, Dr. Ho held leadership positions at two other organizations, Medidata Solutions Inc.and Pfizer Inc. Dr. Ho was also the Founder and Chief Executive Officer of Context Matters Inc., a global life sciences market access software company, which was later acquired by Decision Resources Group in 2017 and then later combined with Clarivate PLC in 2020. Dr. Ho began her career as an emergency medicine physician before deciding to pursue opportunities in the emerging e-health industry. Dr. Ho currently serves on the board of directors of Genesis Research, a real-world evidence research company supporting the life sciences industry, and non-profit PS3til6 and as an advisor to Redesign Health. She received her B.A. from Brown University, her M.D. from Yale University School of Medicine, and her M.B.A. from Harvard Business School. Dr. Ho has served on the Board since February 2023.